| 应用 |
A selective, potent, and irreversible ErbB2 and EGFR inhibitor. |
| 产品介绍 |
Mubritinib (TAK 165)是一种有效的HER2/ErbB2抑制剂，IC50为6 nM；对EGFR， FGFR， PDGFR， JAK1， Src和Blk没有抑制活性。 |
| 备注 |
Mubritinib (TAK-165) is a potent inhibitor of HER2/ErbB2 with IC50 of 6 nM; no activity to EGFR, FGFR, PDGFR, JAK1, Src and Blk. |
| 生化机理 |
TAK 165 is a potent Neu (HER2) and Cdc2 p34 inhibitor with IC50 of 6 nM and 0.2μM, respectively. TAK 165 also inhibits Cdk2 (p33cdk2) and Cdk5 (p33cdk5). TAK 165 displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. TAK 165 exhibits potent antiproliferative effects in Neu-overexpressing cancer cell lines (IC50 = 5 nM in BT474 breast cancer cells) and significantly inhibits bladder, breast and prostate cancer xenograft growth. |
| 别名 |
TAK 165;TAK165;木利替尼; 1-(4-(4-((2-((1E)-2-(4-(三氟甲基)苯基)乙烯基)-4-恶唑基)甲氧基)苯基)丁基)-1H-1,2,3-三氮唑;TAK 165; TAK165;1-(4-(4-((2-((1E)-2-(4-(Trifluoromethyl)phenyl)ethenyl)-4-oxazolyl)methoxy)phenyl)butyl)-1H-1,2,3-triazole |
